A FIC monoclonal antibody targeting solid tumors such as breast cancer and lung cancer. The scientific discoveries underlying the BT02 target represent breakthroughs in the understanding of T cell functional suppression, immune privilege and tumor immune evasion. The MOA of BT02 is shown on the right.
